Fast Retailing Reports Third-Quarter Results

1 Mins read

By Kosaku Narioka

Fast Retailing, the owner of Uniqlo, has announced its third-quarter results. Here’s an overview of the key details:

Net Profit

The company disclosed that its net profit for the quarter ended May 31 decreased by 6.4% compared to the same period last year, amounting to ¥85.1 billion ($614.4 million). This surpassed the estimate of ¥70.23 billion from a FactSet poll of analysts.


Third-quarter revenue experienced a significant increase of 24% from the previous year, reaching ¥676.1 billion. This figure exceeded the estimated revenue of ¥633.14 billion according to the FactSet poll.


China Performance

Fast Retailing reported that its Uniqlo business in China performed remarkably well and exceeded expectations. Same-store sales in mainland China surged by over 40% compared to the previous year, attributed to a recovery in consumer spending following the pandemic-induced slump. The demand for summer clothing also contributed to this growth.


Based on the strong third-quarter results, Fast Retailing has revised its revenue and net profit forecasts for the fiscal year ending in August. The company now anticipates a 19% increase in revenue, projecting it to reach ¥2.730 trillion, while expecting a 4.9% decrease in net profit to ¥260.00 billion.


Fast Retailing has raised its dividend forecast for the fiscal year. The new dividend forecast is ¥280.00 per share, up from the previous forecast of ¥250.00 per share. In the previous fiscal year, the company paid out ¥206.67 per share.

Related posts

First Solar Inc. Financial Report

1 Mins read
First Solar Inc. saw its shares rise more than 5% during the extended session on Tuesday, showing investor optimism for the future…

AMC Entertainment Holdings Inc. Quarterly Results Awaited

1 Mins read
Shares of AMC Entertainment Holdings Inc. have surged 5.9% on Tuesday, marking a three-day winning streak and the largest daily percentage increase…

Theratechnologies FDA Rejection

1 Mins read
Theratechnologies is poised for a significant setback as the Food and Drug Administration (FDA) has rejected its supplemental biologics license application for…

Leave a Reply

Your email address will not be published. Required fields are marked *

27 − = 19